A phase I clinical trial has shown that re-infusion of ex vivo TKD/IL-2 stimulated autologous NK cells in patients with late-stage colorectal cancers and NSCLC is feasible, safe, and well tolerated (29). The gene discussed is IL2; the disease is colorectal cancer.